Will we ever know if leukoreduction of red blood cells should be performed?;Saurons-nous un jour s'il faut procéder à la ré duction leucocytaire des culots globulaires?

Canadian Journal of Anesthesia

Volumn 51, Issue 5, 2004, Pages 407-410

  Carson, Jeffrey L ^a   Berlin, Jesse A ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ALLOIMMUNIZATION; BLOOD FILTRATION; BLOOD STORAGE; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; EDITORIAL; ERYTHROCYTE TRANSFUSION; HEMODILUTION; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTENSIVE CARE; LEUKAPHERESIS; LEUKOCYTE; META ANALYSIS; OUTCOMES RESEARCH; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 2342533054     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03018300     Document Type: Editorial

References (23)

1. Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized clinical trials. Can J Anesth 2004; 51: 417-24.
2. Boomgaard MN, Gouwerok CW, Palfenier CH, et al. Pooled platelet concentrates prepared by the platelet-rich-plasma method and filtered with three different filters and stored for 8 days. Vox Sang 1995; 68: 82-9.
3. Opelz G, Vanrenterghem Y, Kirste G, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997; 63: 964-7.
4. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84: 1703-21.
5. Brecher ME, Pineda AA, Torloni AS, et al. Prestorage leukocyte depletion: effect on leukocyte and platelet metabolites, erythrocyte lysis, metabolism, and in vivo survival. Semin Hematol 1991; 28(3 Suppl 5): 3-9.
6. Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995; 91: 1000-5.
7. Smith KJ, Sierra ER, Nelson EJ. Histamine, IL-1, and IL-8 increase in packed RBCs stored for 42 days, but not in RBCs leukodepleted pre-storage. Transfusion 1993; 33: 53S.
8. Blajchman MA, Bardossy L, Carmen R, et al. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993; 81: 1880-2.
9. Bordin JO, Bardossy L, Blajchman MA. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood 1994; 84: 344-8.
10. Opelz G, Sengar DP, Mickey MR, Yerasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplantation Proceedings 1973; 5: 253-9.
11. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001; 41: 691-712.
12. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513-6.
13. Jensen LS, Hokland M, Nielsen HJ. A randomized controlled study of the effect of bedside leucocyte depletion on the immunosuppressive effect of whole blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1996; 83: 973-7.
14. van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97: 562-8.
15. Fergusson D, Hebert PC, Lee SK, et al. Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA 2003; 289: 1950-6.
16. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289: 1941-9.
17. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
18. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9.
19. Fung MK, Rao N, Rice J, et al. Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study. Transfusion 2004; 44: 30-5.
20. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004; 44: 25-9.
21. Paylino JC, Pomper GJ, Fisch GS, et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44: 16-24.
22. Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44: 10-5.
23. Klein HG. Will blood transfusion ever be safe enough? JAMA 2000; 284: 238-40.